Design Therapeutics (DSGN)
US Market

Design Therapeutics (DSGN) Stock Price & Analysis


DSGN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.90 - $26.30
Previous Close$5.63
Average Volume (3M)378.25K
Market Cap
Enterprise Value$22.60M
Total Cash (Recent Filing)$315.39M
Total Debt (Recent Filing)$2.88M
Price to Earnings (P/E)-4.5
Nov 07, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding55,945,551
10 Day Avg. Volume177,768
30 Day Avg. Volume378,247
Standard Deviation0.19
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.31
Price Target Upside370.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Design Therapeutics’s price range in the past 12 months?
Design Therapeutics lowest stock price was $4.90 and its highest was $26.30 in the past 12 months.
    What is Design Therapeutics’s market cap?
    Currently, no data Available
    When is Design Therapeutics’s upcoming earnings report date?
    Design Therapeutics’s upcoming earnings report date is Nov 07, 2023 which is in 159 days.
      How were Design Therapeutics’s earnings last quarter?
      Design Therapeutics released its earnings results on May 09, 2023. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.358 by $0.008.
        Is Design Therapeutics overvalued?
        According to Wall Street analysts Design Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Design Therapeutics pay dividends?
          Design Therapeutics does not currently pay dividends.
          What is Design Therapeutics’s EPS estimate?
          Design Therapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Design Therapeutics have?
          Design Therapeutics has 55,945,553 shares outstanding.
            What happened to Design Therapeutics’s price movement after its last earnings report?
            Design Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.358. Following the earnings report the stock price went down -11.656%.
              Which hedge fund is a major shareholder of Design Therapeutics?
              Among the largest hedge funds holding Design Therapeutics’s share is RA Capital Management. It holds Design Therapeutics’s shares valued at 17M.


                Design Therapeutics Stock Smart Score

                The Design Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Design Therapeutics

                Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.


                Top 5 ETFs holding DSGN

                Market Value
                Smart Score
                Schwab U.S. Broad Market ETF
                iShares Russell 3000 ETF
                Invesco Nasdaq Biotechnology ETF
                Up to five ETFs with an Outperform Smart Score that hold DSGN. The ETFs are listed according to market value of DSGN within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                IGM Biosciences
                Enanta Pharmaceuticals
                Cogent Biosciences
                Arcellx Inc

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis